Sherene Loi
Sherene Loi/LinkedIn

Sherene Loi: A New Hope Becomes the New World Order in HER2 – Positive Breast Cancer

Sherene Loi, Medical Oncologist, Lab Head of Breast Oncology Clinical Trials at Peter MacCallum Cancer Centre, Australia, shared a post by Paolo Tarantino, adding:

T-DXd: A New Hope becomes the New World Order in HER2 – Positive BC.

3 big read outs for T-Dxd in breast cancer Where will we place T-Dxd preferentially if avail. and all data looks good?

1) residual disease

2) 1L metastatic

3) neoadjuvant with TCHP

Vote (pre ESMO).”

Quoting Paolo Tarantino‘s post:

“After improving OS for patients with metastatic disease, the topo1 ADC wave is now reaching its most ambitious goal: preventing recurrence.

DB-05 is positive: adjuvant T-DXd improves iDFS over T-DM1.

No info on ILD in the press release. Hoping for no G5.”

 Paolo Tarantino

More posts featuring Paolo Tarantino and Sherene Loi on OncoDaily.